Research Roundup: Marburg treatment trial, AMR innovation funding, Shigella vaccine development
Global Health Technologies Coalition (GHTC)
Advancing innovation to save lives
TOP NEWS IN R&D
Marburg treatment trials launch in Rwanda CIDRAP (10/16), features Sabin Vaccine Institute?
Last week, scientists in Rwanda and partners from the World Health Organization launched the world’s first clinical trial testing a treatment for the deadly Marburg virus amid the ongoing outbreak in the country. There are currently no approved treatments or vaccines against Marburg virus, although a clinical trial of Sabin Vaccine Institute’s investigational vaccine is currently underway in Rwanda. The new trial will investigate the safety and efficacy of remdesivir and the monoclonal antibody MBP091, developed by Mapp Biopharmaceutical with support from the Biomedical Advanced Research and Development Authority.?
Italy announces grant to CARB-X at G7 meeting CARB-X press release (10/16)
At the recent G7 Joint Finance and Health Ministers’ Meeting, the Italian government announced a $21 million commitment over the next three years to the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) to accelerate the development of innovative products to prevent, diagnose, and treat drug-resistant bacterial infections. AMR is a growing public health crisis, particularly in low- and middle-income countries, and there is an urgent need for international collaboration and investment to revitalize an inadequate clinical pipeline and ensure new antimicrobials, antimicrobial alternatives, and diagnostics are available for patients worldwide.?
Valneva and LimmaTech awarded FDA Fast Track designation for tetravalent Shigella vaccine candidate S4V Valneva press release (10/16)
Valneva and LimmaTech announced last week that their Shigella4V (S4V) vaccine has been awarded Fast Track designation by the US Food and Drug Administration. There are no approved vaccines for the Shigella bacteria, which causes shigellosis, the second leading cause of fatal diarrheal disease globally, particularly among children in low- and middle-income countries. S4V is the world’s most clinically advanced tetravalent bioconjugate vaccine for shigellosis. This designation will enable accelerated clinical development and review of the vaccine, which will be investigated in two Phase 2 trials that are expected to begin before the end of 2024.???
NEWS FROM GHTC
Imperial?(10/17), features the Coalition for Epidemic Preparedness Innovations (CEPI)
Science?(10/16), features the Sabin Vaccine Institute
CIDRAP?(10/16), features CARB-X?and the Global Antibiotic Research & Development Partnership
Devex?(10/16), features the Bill & Melinda Gates Foundation
CEPI press release?(10/15)
Nature?(10/14), features the Gates Foundation
CIDRAP?(10/14), features the Sabin Vaccine Institute
HIGHLIGHTS FROM THE WEEK
360Dx?(10/18)
CIDRAP?(10/18)
CIDRAP?(10/18)
Fierce Biotech?(10/17)
Science Daily?(10/17)
Fierce Biotech?(10/16)
Fierce Parma?(10/16)
领英推荐
CIDRAP?(10/15)
Devex?(10/14)
AVIAN FLU R&D ROUNDUP
The Telegraph?(10/17)
CIDRAP?(10/16)
CIDRAP?(10/15)
MedicalXpress?(10/14)
MPOX R&D ROUNDUP
National Institute of Allergy and Infectious Diseases news release (10/16)
UPCOMING EVENTS
October 22
Raleigh, NC
November 13-17
New Orleans, LA
November 18-21
Virtual; Washington, DC
December 5
Tokyo, Japan
February 4-5
Virtual
Interested in more global health innovation news? Every week GHTC scours media reports worldwide to deliver essential global health R&D news and content to your inbox. Subscribe to receive our weekly R&D News Roundup.